Abstract:Transforming the gene editing technology into therapeutic uses encounters several obstacles including the concern over safety. These gene editing platforms, such as the Cas9/sgRNA system, have been shown to induce off-target DNA double-stranded breaks (DSBs) throughout genomes, which is associated with toxicity. Such off-target effects not only stem from the intrinsic ambiguity of DNA sequence recognition by nucleases, but also attribute to the prolonged presence of an active gene editing system in a given cell. As a result, off-target DSBs accumulate over time, and ultimately lead to genotoxicity. To mitigate the potential toxicity due to prolonged expression of a gene editing system in vivo, we sought to transiently deliver the key component, i.e. the endonuclease protein, which will fulfill the task of inducing permanent gene editing followed by natural degradation. Specifically, we use the VP2 protein of AAV capsid as a protein delivery vehicle to ferry the Cas9 protein in vivo. We first constructed a sensitive gene editing reporter plasmid, and demonstrated that co-transfection of the reporter plasmid and a plasmid expressing the SpCas9-VP2 fusion protein induced gene editing in HEK293 cells. We then modified our rAAV packaging system to include a plasmid expressing VP1 and VP3, and another plasmid expressing either the SpCas9-VP2 fusion protein or the EGFP-VP2 fusion protein. We successfully produced EGFP-AAV2 (EGFP protein grafted on the AAV2 capsid). However, we were not able to produce rAAV particles carrying SpCas9 protein, likely because the large size of SpCas9 protein interfered with the AAV packaging process. Therefore, we split SpCas9 into halves aiming to utilize split intein-mediated protein trans-splicing (PTS) to transiently reconstitute the full-length SpCas9 (Figure). When the two parts of a split intein (termed IntN and IntC, respectively) fused with two proteins, the split intein is able to mediate PTS, resulting in the generation of a fusion protein with the intein being spliced out. We generated plasmids expressing the fusion proteins SpCas9N-IntN and IntC-SpCas9C-VP2, respectively, and demonstrated productive intein-mediated reconstitution of SpCas9-VP2 protein in HEK293 cells by co-transfection. Importantly, co-transfection of plasmids expressing SpCas9N-IntN and IntC-SpCas9C-VP2 in HEK293 cells led to gene editing based on the reporter assay. Guided by structural analysis and prediction, we strategically screened and identified the SpCas9 split sites close to the C-term of SpCas9. Therefore, the IntC-SpCas9C protein to be grafted on VP2 is equal or smaller than EGFP. Because we were able to produce EGFP-AAV2, we reasoned that the IntC-SpCas9C-VP2 will likely be amenable to the rAAV packaging process, which is underway. If successful, our novel off-target mitigating strategy described here will greatly facilitate the translational application of gene editing technology in vivo. In addition, this transient in vivo protein reconstitution approach is applicable to the delivery of therapeutic but highly toxic proteins for the treatment of cancer and other diseases.

Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo

Self-delivering, chemically modified CRISPR RNAs for AAV co-delivery and genome editing in vivo

Precision genome editing using combinatorial viral vector delivery of CRISPR-Cas9 nucleases and donor DNA constructs

AAV-mediated gene therapies by miniature gene editing tools

Viral delivery of compact CRISPR-Cas12f for gene editing applications

<i>In vivo PCSK9</i> gene editing using an all-in-one self-cleavage AAV-CRISPR system

The Role of Recombinant AAV in Precise Genome Editing

Adenine Base Editing in vivo with a Single Adeno-Associated Virus Vector

CRISPR-Cas12a System With Synergistic Phage Recombination Proteins for Multiplex Precision Editing in Human Cells

AAV-mediated in vivo genome editing in vascular endothelial cells.

Development Of Highly Efficient Dual-Aav Split Adenosine Base Editor For In Vivo Gene Therapy

570. Transient Reconstitution of Cas9 Protein for Safer Gene Editing in Vivo - A Ferry Tale Starring Raav Capsid

In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease

Delivery of CRISPR/Cas9 system by AAV as vectors for gene therapy

Cytosine and Adenine Base Editing of the Brain, Liver, Retina, Heart and Skeletal Muscle of Mice Via Adeno-Associated Viruses

Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor

Engineering Human ARMMs as Therapeutic Non-Viral Vehicles for in vivo Delivery of Genome Editing Payloads

AAV vector-derived elements integrate into Cas9-generated double-strand breaks and disrupt gene transcription

Engineering single-cycle MeV vector for CRISPR-Cas9 gene editing

All-in-one AAV-delivered epigenome-editing platform: proof-of-concept and therapeutic implications for neurodegenerative disorders

Abstract 106: Efficient in Vivo Homology-Directed Repair Within Cardiomyocytes